239 related articles for article (PubMed ID: 20615626)
21. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value.
Markova J; Kobe C; Skopalova M; Klaskova K; Dedeckova K; Plütschow A; Eich HT; Dietlein M; Engert A; Kozak T
Ann Oncol; 2009 Jul; 20(7):1270-4. PubMed ID: 19228806
[TBL] [Abstract][Full Text] [Related]
22. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
[TBL] [Abstract][Full Text] [Related]
23. A prospective study of ¹⁸FDG-PET with CT coregistration for radiation treatment planning of lymphomas and other hematologic malignancies.
Terezakis SA; Schöder H; Kowalski A; McCann P; Lim R; Turlakov A; Gonen M; Barker C; Goenka A; Lovie S; Yahalom J
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):376-83. PubMed ID: 24726287
[TBL] [Abstract][Full Text] [Related]
24. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging.
Scarfone C; Lavely WC; Cmelak AJ; Delbeke D; Martin WH; Billheimer D; Hallahan DE
J Nucl Med; 2004 Apr; 45(4):543-52. PubMed ID: 15073248
[TBL] [Abstract][Full Text] [Related]
25. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
[TBL] [Abstract][Full Text] [Related]
26. Impact of FDG-PET/CT fused imaging on tumor volume assessment of head-and-neck squamous cell carcinoma: intermethod and interobserver variations.
Murakami R; Uozumi H; Hirai T; Nishimura R; Katsuragawa S; Shiraishi S; Toya R; Tashiro K; Kawanaka K; Oya N; Tomiguchi S; Yamashita Y
Acta Radiol; 2008 Jul; 49(6):693-9. PubMed ID: 18568563
[TBL] [Abstract][Full Text] [Related]
27. [Evolution in 18F-FDG-PET of a case of Hodgkin disease, nodular sclerosis variety, after treatment and autotrasplant].
Sánchez-Salmón A; Barandela J; Garrido M; Ciobotaru AB; Albo C; Ruibal A
Rev Esp Med Nucl; 2007; 26(3):165-8. PubMed ID: 17524311
[TBL] [Abstract][Full Text] [Related]
28. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease.
Advani R; Maeda L; Lavori P; Quon A; Hoppe R; Breslin S; Rosenberg SA; Horning SJ
J Clin Oncol; 2007 Sep; 25(25):3902-7. PubMed ID: 17664458
[TBL] [Abstract][Full Text] [Related]
29. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
[TBL] [Abstract][Full Text] [Related]
30. (18)F-FDG PET-CT simulation for non-small-cell lung cancer: effect in patients already staged by PET-CT.
Hanna GG; McAleese J; Carson KJ; Stewart DP; Cosgrove VP; Eakin RL; Zatari A; Lynch T; Jarritt PH; Young VA; O'Sullivan JM; Hounsell AR
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):24-30. PubMed ID: 19665324
[TBL] [Abstract][Full Text] [Related]
31. An unusual case of spontaneous remission of Hodgkin's disease after a single cycle of COPP-ABV chemotherapy followed by infectious complications.
Bang SM; Cheong JW; Yang WI; Hahn JS
Yonsei Med J; 2005 Jun; 46(3):425-30. PubMed ID: 15988816
[TBL] [Abstract][Full Text] [Related]
32. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.
Raemaekers JM; André MP; Federico M; Girinsky T; Oumedaly R; Brusamolino E; Brice P; Fermé C; van der Maazen R; Gotti M; Bouabdallah R; Sebban CJ; Lievens Y; Re A; Stamatoullas A; Morschhauser F; Lugtenburg PJ; Abruzzese E; Olivier P; Casasnovas RO; van Imhoff G; Raveloarivahy T; Bellei M; van der Borght T; Bardet S; Versari A; Hutchings M; Meignan M; Fortpied C
J Clin Oncol; 2014 Apr; 32(12):1188-94. PubMed ID: 24637998
[TBL] [Abstract][Full Text] [Related]
33. Intraobserver and interobserver variability in GTV delineation on FDG-PET-CT images of head and neck cancers.
Breen SL; Publicover J; De Silva S; Pond G; Brock K; O'Sullivan B; Cummings B; Dawson L; Keller A; Kim J; Ringash J; Yu E; Hendler A; Waldron J
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):763-70. PubMed ID: 17379435
[TBL] [Abstract][Full Text] [Related]
34. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
Zinzani PL; Zompatori M; Bendandi M; Battista G; Fanti S; Barbieri E; Gherlinzoni F; Rimondi MR; Frezza G; Pisi P; Merla E; Gozzetti A; Canini R; Monetti N; Babini L; Tura S
Leuk Lymphoma; 1996 Jun; 22(1-2):131-5. PubMed ID: 8724540
[TBL] [Abstract][Full Text] [Related]
35. [Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers].
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Cancer Radiother; 2005 Sep; 9(5):304-15. PubMed ID: 16087377
[TBL] [Abstract][Full Text] [Related]
36. Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy.
Leclerc M; Lartigau E; Lacornerie T; Daisne JF; Kramar A; Grégoire V
Radiother Oncol; 2015 Jul; 116(1):87-93. PubMed ID: 26088157
[TBL] [Abstract][Full Text] [Related]
37. 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiotherapy target volume definition in non-small-cell lung cancer: delineation by radiation oncologists vs. joint outlining with a PET radiologist?
Hanna GG; Carson KJ; Lynch T; McAleese J; Cosgrove VP; Eakin RL; Stewart DP; Zatari A; O'Sullivan JM; Hounsell AR
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1040-51. PubMed ID: 20350798
[TBL] [Abstract][Full Text] [Related]
38. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
[TBL] [Abstract][Full Text] [Related]
39. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
[TBL] [Abstract][Full Text] [Related]
40. Improving observer variability in target delineation for gastro-oesophageal cancer--the role of (18F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
Vesprini D; Ung Y; Dinniwell R; Breen S; Cheung F; Grabarz D; Kamra J; Mah K; Mansouri A; Pond G; Brock K; Darling G; Knox J; Haider M; Wong RK
Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):631-8. PubMed ID: 18755578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
